Archive for the ‘Treatment’ Category

Study: Oral NAD+ & NMN Increases Intracellular NAD+ & Lowers Triglycerides

https://www.townsendletter.com/e-letter-17-nad_plus-supplementation-and-cellular-energy/

Case Study: Oral Supplementation with the NAD+ Precursor Nicotinamide Mononucleotide (NMN)—Effects on Intracellular NAD+ and Triglycerides.

Alan Miller, ND

Abstract

NAD+ is a coenzyme that is essential in numerous metabolic reactions, the most important involving energy production. In the cellular respiration process, NAD+ is required for the production of ATP (adenosine triphosphate), the primary energy currency of cells. NAD+ transfers electrons from molecules including glucose during glycolysis and the citric acid cycle. These electrons are then transferred to the electron transfer chain, where NAD+ acts as an essential mediator in energy production, ensuring the efficient functioning of cells. NAD+ is also critically involved in DNA repair and healthy aging sirtuin enzymes.

Nicotinamide Mononucleotide (NMN) is the most direct biochemical precursor to NAD+ and thus supplementation of this molecule is an efficient method of increasing intracellular NAD+, which can improve cellular energetics and markers of aging. NMN may also lower triglycerides. In a study of intravenous dosing of 300 mg NMN in 10 healthy individuals, researchers discovered a significant reduction in serum triglycerides.

One concern with NMN is that when taken in an oral dose this molecule might be damaged or otherwise metabolized by stomach acid, pancreatic enzymes, or first pass hepatic enzymes. In other studies, we have shown that a liposomal powder preparation can protect other molecules, such as glutathione, from this type of degradation and significantly increase blood levels of the whole molecule.

We performed a small case study in which individuals were given 1000 mg of an oral liposomal NMN preparation (powder in a capsule) once after a baseline blood test. Serial triglyceride tests were performed hourly for five hours. Participants had an average of 15% decrease in triglycerides at hour five, compared to baseline. Another group was tested at baseline for intracellular NAD+ (Jinfinity Labs), then was given 1000 mg of a liposomal powder NMN daily for 15 days. An intracellular NAD+ test was then performed after 15 days. NAD+ levels increased 100 percent over this period.

This is the first case series that has demonstrated a rapid triglyceride-lowering effect of oral liposomal NMN (over 5 hours), along with a 100-percent increase in intracellular NAD+ over a 15-day period.

(See link for full article)

For more:

The COVID Clots: A Full Measure Town Hall

http://  Approx. 52 Min

The COVID Clots

Sept. 12, 2023

**If Youtube censors this video, go here to learn where to watch Full Measure**

Full Measure host Sharyl Attkisson is joined by a panel of experts to discuss emerging research and treatments related to COVID-19 and COVID-19 vaccines.

Hear directly from patients and doctors.  Highly worth your time.

Similarly to Lymeland, COVID “vaccine” injured are having to find, seek out, and travel to doctors willing to admit they are injured, and treat them.

The internal medicine doctor (Dr. Jordan Vaughn, Alabama, CEO & owner of MedHelp Clinics and The Microvascular Research Foundation for Spike Protein & Long COVID) who spoke stated that they were told COVID was an upper respiratory tract infection, but it causes a lot of other dysfunction, including vascular issues.

In short, both the infection AND the shots are giving people issues with fibrin – the substance responsible for the clotting mechanism in the body.  Instead of creating soft, spaghetti-like structures that are drained through a colander with holes and space, the infected and the injected are creating burnt-spaghetti-like structures with melted cheese stuck together that lacks space and holes and is resistant to being broken down.

Go here for resources from the program.  Within this link is the following info which was interesting to me due to my own experience:

Iliac Vein Compression

Iliac vein compression isn’t new or uncommon. But when you introduce microclots [related to Covid or Covid vaccine spike protein], this compressed vein becomes compromised. The result? Decreased blood flow that leads to inflammation, additional clots, urinary urgency, chronic pain, POTS, and difficulty walking. Current treatments are effective, but invasive and costly. We’re hoping to find a better way.

The left iliac vein, which sits underneath the right iliac artery in the pelvis, can become compressed independent of a COVID-19 infection. However, the introduction of the spike protein can lead to damage of the vessel walls that inhibits blood flow to the extremities.

And my experience was developing pain, exactly in this area, after being seated on a bike for a long time.  Although unvaxxed, I’ve had COVID multiple times.

Also similarly to Lymeland, symptoms will manifest on people differently due to where these clots are forming.  So for one patient, it could be in their eyes affecting their vision. For another, it could be in their brain where it will cause completely different symptoms, or in an extremity where they might have difficulty walking, or the lungs making it difficult to breathe.  So of course, few doctors are putting it all together.

Attkisson has a new book coming out April, 2024 called “Follow the $cience: How Big Pharma Misleads, Obscures, and Prevails.”

Follow the Science will challenge your assumptions, open your eyes, and inspire you to take action. With its powerful message of truth and justice, this book is a must-read for anyone who cares about the future of our healthcare system.

For more:

Again, the information is out there for those with an ear to hear.

As Lyme Disease Expands Its Reach, New Research Offers Hope (But Not Really)

https://jamanetwork.com/journals/jama/fullarticle/2809395

Medical News & Perspectives
Climate Change and Health
September 6, 2023

As Lyme Disease Expands Its Reach, New Research Offers Hope

JAMA. Published online September 6, 2023. doi:10.1001/jama.2023.15358

Public health warnings about vector-borne diseases in the US are heating up. In a May editorial, scientists from the Centers for Disease Control and Prevention (CDC) made a plea for a vaccine against West Nile virus, which is spread by mosquitoes and has no treatment. By midsummer, the CDC reported that as many as 450 000 people in the US may have a meat allergy from the bite of the lone star tick, while other CDC scientists warned that mosquitoes are becoming resistant to the insecticides used in abatement efforts. Mosquitoes struck in August, when public health officials reported 11 cases of locally acquired dengue fever in Florida and Maryland’s first known case of locally acquired malaria in more than 40 years.

Meanwhile, the most common vector-borne disease in the US, Lyme disease, is on the rise.

“Lyme disease is definitely increasing in the US as the environmental niche of the deer tick and deer populations expand,” John N. Aucott, MD, director of the Lyme Disease Research Center at the Johns Hopkins University School of Medicine, told JAMA in an interview. The incidence of Lyme disease in the US nearly doubled from 1991 to 2018, from 3.74 cases to 7.21 cases per 100 000 people, based on confirmed cases reported to the CDC. But the true numbers are believed to be much higher.

According to the nonprofit organization Fair Health, US private insurance claims with a Lyme disease diagnosis increased 357% in rural areas and 65% in urban areas from 2007 to 2021. Using insurance claims, the CDC estimates that as many as 476 000 people in the US are diagnosed with and treated for Lyme disease each year.

“In the last 20 years, the numbers of Lyme disease have really exploded,” said Linden Hu, MD, director of the Lyme Disease Initiative at Tufts University School of Medicine. “We’ve seen people get Lyme disease just from stopping at a rest stop in Massachusetts. So the number of people at risk is greater than it was before.”

(See link for article)

___________________

**Comment**

There is very little hope within this article.

Summary:

  • Climate change clap trap continues to be regurgitated and blamed for what we are experiencing, despite ticks being ecoadaptive and the last species to die on planet earth.
  • PTLDS is emphasized only due to the fact there is “no known treatment,” so vaccines can be pushed.
  • The article gives false hope by stating the NIH has announced $3.2 Million in funding to support research on PTLDS; however, what isn’t mentioned is this money will do NOTHING to help patients.  It will simply line the pockets of biased, bought out researchers who will continue with the accepted, politically motivated narrative.
  • The falsely low number of 10-20% who continue with lingering symptoms is regurgitated when the number is upwards of 40-60%.
  • Hu managed to mention the fact that persistent infection after treatment is one hypothesis for PTLDS along with immune responses and autoantibodies.
  • And Aucott also managed to mention that due to his magnetic imaging studies which showed there is underlying biology to explain patients’ symptoms, it is not psychosomatic.
  • Of course nothing would be complete without a huge section on vaccines. (This is getting very old)  It’s also a good time to reflect upon the conflict of interest disclosures:

Dr Hu reported having financial relationships with Moderna and Tarsus. Dr Fikrig reported that he is funded by the NIH, the Cohen Foundation, and the Howard Hughes Medical Institute’s Emerging Pathogens Initiative. Dr Wormser reported receiving research grants from Biopeptides Corp and Pfizer Inc; being an expert witness in malpractice cases involving Lyme disease; and serving as an unpaid board member of the nonprofit American Lyme Disease Foundation.

  • The article made Lymerix seem like the answer to all of life’s ills when in fact it was yanked off the market for causing Lyme-like symptoms.  To those who tout the narrative, Lymerix, like all other vaccines, is “safe and effective.”  (This too is getting extremely old)
  • But, there’s a new vaccine to save humanity in the pipeline! Yay! This “antitick vaccine” encodes a cocktail of 19 proteins in tick saliva What could possibly go wrong?! 
  • Hu is developing lotinaner, used in the veterinary world, of which the FDA has given an alert about potential neurological adverse events, muscle tremors, ataxia, and seizures.
  • Aucott mentioned that the “classic” bullseye rash is a myth as only 20-30% have a bullseye pattern, and that many have no rash at all.  So, sorry all you suckers that didn’t fit in the box, were told you had a spider bite, and sent home empty-handed to suffer in silence.  Oops!
  • Aucott mentons testing problems: test results take 4-8 weeks before an antibody test is definitive, and following treatment – serology results will remain positive.
  • Wormser of course dissuades from prophylactic treatment unless a confirmed deer tick has been attached for 36 hours – the notion of which has been proven to be false.  He’s more worried about staph than people getting Lyme/MSIDS and living a nightmare. Plus, there are other antimicrobials in the toolbox that can be used that wouldn’t promote resistance.
  • Alpha Gal meat allergy is all the rage now because of The Great Reset and the desire to eliminate meat and get us all eating bugsA report has even predicted that the next ‘pandemic’ will conveniently come from meat.  It’s a win, win for ‘the powers that be.’
  • The article falsely blames climate change and the Lone Star tick when other ticks are involved, or even NO ticks at all. They have only discovered that tick saliva contains trace quantities of the sugar alpha-gal a known human irritant that many believe induces an allergic response.
  • But alpha-gal is also is used in the manufacture of foods, personal care products, medical devices and drugs — including vaccines.  Source
  • The questions begging to be asked are: why are they putting this known human irritant in things that humans ingest?  And why the sole emphasis on ticks when it’s in plenty of other things including vaccines, and is only believed to be caused by ticks?
It should come at no surprise whatsoever that the media is suddenly pushing a fear narrative over a meat allergy.
Again – right on time.

Delays in Diagnosis & Treatment of Tick-borne Diseases Due to Impact of COVID Pandemic

https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-023-05917-8

Impact of the COVID-19 pandemic on delays in diagnosis and treatment of tick-borne diseases endemic to southeastern USA

Victor ArahirwaKatherine TyrlikHaley AbernathyCaitlin CassidyAidin AlejoOdai MansourDana GiandomenicoAmanda Brown Marusiak & Ross M. Boyce

Abstract

Background

The Coronavirus disease 2019 (COVID-19) pandemic was marked by an increase in diagnosis and treatment delays for a range of medical conditions. Yet the impact of the pandemic on the management of tick-borne diseases, which frequently manifest as an acute febrile illness similar to COVID-19, has not been well described.

Methods

In this retrospective cohort study of patients with suspected tick-borne disease attending the University of North Carolina Health facilities, we compared the timeliness of diagnosis and treatment in a “pre-COVID” period (March 2019 to February 2020) and a “post-COVID” period (March 2020 to February 2021). Participants included patients with an ICD-10 diagnosis code of spotted fever group rickettsiosis or ehrlichiosis and a positive Rickettsia rickettsii or Ehrlichia indirect immunofluorescence assay immunoglobulin G antibody test result. Of the 897 patients who had an eligible diagnosis, 240 (26.8%) met the inclusion criteria. The main outcome was time from initial presentation to definitive diagnosis and treatment.

Results

During the 2-year study period, 126 (52.5%) patients were grouped in the pre-COVID period and 114 (47.5%) were grouped in the post-COVID period; 120 (50.0%) were female; and 139 (57.9%) were aged > 50 years. Comparing the post-COVID to the pre-COVID period, the adjusted odds ratio (aOR) for delay in treatment > 0 days was 1.81 (95% confidence interval [CI] 1.07–3.07, P = 0.03), and for a treatment delay > 7 days, 1.65 (95% CI 0.94–2.90, P = 0.08). The odds of a delay in diagnosis were similar for patients in the post- and pre-COVID periods, with an aOR of 1.61 (95% CI 0.96–2.72, P = 0.07) for delays > 0 days, and aOR of 1.72 (95% CI 0.99–3.00, P = 0.05) for delays > 7 days.

Conclusions

The odds of a delay in treatment > 0 days were significantly higher in the post-COVID period than in the pre-COVID period. However, the odds of a delay in treatment > 7 days, or a delay in diagnosis, were similar between these two periods. Shifts in care-seeking, alternative care delivery models and prioritization of COVID-19 may contribute to diminished timeliness of treatment for patients with tick-borne diseases.

For more:

Lactate Dehydrogenase Inhibitors Suppress Bb Growth In Vitro

https://www.mdpi.com/2076-0817/12/7/962

Lactate Dehydrogenase Inhibitors Suppress Borrelia burgdorferi Growth In Vitro

1Department of Microbiology, University of Massachusetts, Amherst, MA 01003, USA
2Department of Biochemistry, University of Massachusetts, Amherst, MA 01003, USA
3Invasive Insect Biocontrol & Behavior Laboratory, USDA-ARS, Beltsville, MD 20705, USA
*
Author to whom correspondence should be addressed.
Pathogens 202312(7), 962; https://doi.org/10.3390/pathogens12070962
Received: 25 June 2023 / Revised: 15 July 2023 / Accepted: 19 July 2023 / Published: 22 July 2023
(This article belongs to the Section Ticks)

Abstract

Borrelia burgdorferi, the causative agent of Lyme disease, has a highly reduced genome and relies heavily on glycolysis for carbon metabolism. As such, established inhibitors of lactate dehydrogenase (LDH) were evaluated in cultures to determine the extent of their impacts on B. burgdorferi growth. Both racemic and enantiopure (AT-101) gossypol, as well as oxamate, galloflavin, and stiripentol, caused the dose-dependent suppression of B. burgdorferi growth in vitro. Racemic gossypol and AT-101 were shown to fully inhibit spirochetal growth at concentrations of 70.5 and 187.5 μM, respectively. Differences between racemic gossypol and AT-101 efficacy may indicate that the dextrorotatory enantiomer of gossypol is a more effective inhibitor of B. burgdorferi growth than the levorotatory enantiomer. As a whole, LDH inhibition appears to be a promising mechanism for suppressing Borrelia growth, particularly with bulky LDH inhibitors like gossypol.  (See link for article)
_______________
**Comment**
Lactate dehydrogenase inhibitors (LDH) are used in various assays for cancer and other research areas. They are also a promising target for cancer therapy.
For more: